Manzer competitive analysis

Explore patent oppositions filed by Manzer against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 6, 2026
Patent NumberTitleApplicantOpposition Date
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 13, 2026

Latest PTAB cases involving Manzer

Discover the latest PTAB cases involving Manzer, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Manzer with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 6, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MANZER1 - - -
BRISTOL MYERS SQUIBB - 90 - 8